Lack of Association of the Cyclooxygenase-2 Gene 8473T&gt;C Polymorphism with Breast Cancer Risk: a Meta-analysis

Yang, Xi; Zhao, Fen; Li, Yuehua; Huang, Min; Huang, Ying; Yi, Cheng

doi:10.7314/apjcp.2014.15.22.9693

Cited by 2 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The identified SNP (rs2069762) is in the promoter region of IL2 and the expression of the T allele results in decreased IL2 production, shifting the Th1/Th2 balance of immune response towards the Th2 subtype, as frequently reported in atopic subjects (Christensen et al, 2006). The expression of the T allele of this SNP has been linked with predisposition to allergic diseases (Christensen et al, 2006), asthma and atopic eczema in a Danish cohort; although it is not associated with cancer risk, it could represent a possible mechanism to understand the pathophysiology of bendamustine-related skin rash (Christensen et al, 2006;Wang et al, 2015).…”

Section: Discussionmentioning

confidence: 74%

Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non‐hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab

et al. 2018

View full text Add to dashboard Cite

Bendamustine is used in combination with rituximab (BR) to treat indolent non-Hodgkin lymphomas (iNHL) and mantle cell lymphoma (MCL). The variability in treatment efficacy and toxicity could be related to single nucleotide polymorphisms (SNPs) in immune response genes. We would like to show a correlation between SNPs and treatment outcome in iNHL and MCL patients receiving BR. We investigated some SNPs that had already been associated with NHL outcome. Samples were genotyped for the IL2 (rs2069762), IL10 (rs1800890, rs10494879), VEGFA (rs3025039), IL8 (rs4073), CFH (rs1065489) and MTHFR (rs1801131) SNPs by allelic discrimination assays. We enrolled 70 patients that received rituximab 375 mg/m and bendamustine 90 mg/m every 28 days, both as first-line treatment and ≥ second-line regimens. Overall response rate was 97·1% (complete response [CR] rate 73·9%). Treatment toxicity included grade 3-4 neutropenia (24/70 patients), infections (21/70 patients; 1/70 grade 3), skin rash (26/70 patients; 2/70 grade 3). After a median follow-up of 24 months we did find any correlation between the analysed SNPs, CR rate and PFS. However, we demonstrated an association between the SNP in IL2 (rs2069762) and the onset of skin rash (P = 0·0001). Our study suggests a role for cytokine SNPs in bendamustine-related toxicity, which could represent a promising research field.

show abstract

Section: Discussionmentioning

confidence: 74%

Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non‐hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab

et al. 2018

View full text Add to dashboard Cite

show abstract

“…A suggestive interaction was detected between nonfermented soy intake and IL2 polymorphism (rs2069762) for gastric cancer risk, especially for intestinal-type. The IL2 gene is an important cytokine family member that plays a critical role in carcinogenesis through the proliferation of activated T lymphocytes and participates in termination of the lymphocyte response by inducing suppressive T cells [ 29 ]. The IL2 gene polymorphism, which is associated with an increased risk of gastric atrophy induced by H. pylori infection, might predispose individuals to gastric cancer [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

“…The IL2 gene polymorphism, which is associated with an increased risk of gastric atrophy induced by H. pylori infection, might predispose individuals to gastric cancer [ 10 ]. Previous studies have investigated the association between rs2069762 polymorphism and cancer risk, but the results remain controversial [ 10 , 29 ]. We found a suggestive interactive effect between by rs2069762 and nonfermented soy consumption on intestinal-type gastric cancer risk, which suggests a possible interactive role between soy phytochemicals and the pro-inflammatory properties of IL2 cytokines.…”

Section: Discussionmentioning

confidence: 99%

Effects of Soy Product Intake and Interleukin Genetic Polymorphisms on Early Gastric Cancer Risk in Korea: A Case-Control Study

et al. 2017

View full text Add to dashboard Cite

PurposeThe current study investigated whether the combined effects of soy intake and genetic polymorphisms of interleukin (IL) genes modify gastric cancer risk.Materials and MethodsA total of 377 cases and 754 controls of Korean origin were included in the analysis. Soy consumption was assessed using a semi-quantitative food frequency questionnaire. Seven variants of IL10 (rs1800871), IL2 (rs2069763 and rs2069762), IL13 (rs6596090 and rs20541), and IL4R (rs7205663 and rs1805010) were genetically analyzed. To analyze the combined effect of soy intake and genetic polymorphisms, a low-intake group and high-intake group of each type of soy were categorized based on the intake level of the control group. Interactions between soy products and these genetic variants were analyzed by a likelihood ratio test, in which a multiplicative interaction term was added to the logistic regression model.ResultsA higher intake of nonfermented soy products was associated with a reduced cancer risk (odds ratio [OR], 0.62; 95% confidence interval [CI], 0.43 to 0.90), and the reduced risk was only apparent in males (OR, 0.44; 95% CI, 0.27 to 0.71). None of the IL genetic polymorphisms examined were independently associated with gastric cancer risk. Individuals with a minor allele of IL2 rs2069762 and a higher intake of nonfermented soy food had a decreased risk of gastric cancer (OR, 0.46; 95% CI, 0.31 to 0.68) compared to those with a lower intake (pinteraction=0.039).ConclusionBased on the genetic characteristics of the studied individuals, the interaction between IL2 rs2069762 and nonfermented soy intake may modify the risk of gastric cancer.

show abstract

Lack of Association of the Cyclooxygenase-2 Gene 8473T>C Polymorphism with Breast Cancer Risk: a Meta-analysis

Cited by 2 publications

References 36 publications

Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non‐hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab

Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non‐hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab

Effects of Soy Product Intake and Interleukin Genetic Polymorphisms on Early Gastric Cancer Risk in Korea: A Case-Control Study

Contact Info

Product

Resources

About